Trials / Completed
CompletedNCT03890003
A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes
An Early Feasibility Study to Evaluate the Predictive Low Glucose Suspend Functionality and Safety in an Automated Insulin Delivery System in Adult Patients With Type 1 Diabetes Mellitus
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this early feasibility study is to assess the predictive low glucose suspend (PLGS) feature's safety, functionality and performance.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | AID System | AID system |
| DRUG | Insulin Lispro | Individualized doses of insulin lispro administered via the AID system to maintain glycemic control, except during procedures designed to induce hyperglycemia and hypoglycemia. |
Timeline
- Start date
- 2019-03-28
- Primary completion
- 2019-05-06
- Completion
- 2019-05-06
- First posted
- 2019-03-26
- Last updated
- 2019-06-05
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT03890003. Inclusion in this directory is not an endorsement.